Nisa Investment Advisors LLC Boosts Holdings in Solventum Co. (NYSE:SOLV)

Nisa Investment Advisors LLC increased its position in Solventum Co. (NYSE:SOLV) by 2.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,546 shares of the company’s stock after purchasing an additional 708 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Solventum were worth $2,216,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Copeland Capital Management LLC purchased a new position in Solventum in the 3rd quarter valued at about $26,000. Modus Advisors LLC purchased a new position in Solventum in the fourth quarter valued at about $25,000. Mather Group LLC. acquired a new stake in Solventum during the 3rd quarter valued at approximately $27,000. True Wealth Design LLC increased its holdings in Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares during the last quarter. Finally, Prospera Private Wealth LLC acquired a new position in shares of Solventum in the 3rd quarter valued at approximately $35,000.

Solventum Trading Up 1.8 %

Shares of NYSE SOLV opened at $74.93 on Monday. The firm’s 50-day moving average price is $69.56 and its two-hundred day moving average price is $66.43. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.23). The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. On average, research analysts predict that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on SOLV shares. Morgan Stanley raised their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Mizuho began coverage on shares of Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. Stifel Nicolaus started coverage on shares of Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Finally, Piper Sandler lifted their price target on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.